This Pharma Exec Is Accused Of Fixing Prices On 107 Drugs

Quick Read

Aaron Troy writes, “Trump administration recently finalized a rule that will require drug makers to show a medication’s list price. As a future physician, I am against this change. Adding the information would make the ads less helpful and more confusing for patients, who are powerless to change the complex system…”

Quick Read

Novartis AG is expected to begin selling Zolgensma, a possible cure for spinal muscular atrophy, after the FDA approves it this month. Novartis executives say Zolgensma’s ability to curb SMA—a muscle-wasting disease that often kills babies before age 2—explains the eye-popping price

Quick Read

Setting US drug prices based on prices paid in other countries could also improve affordability for Medicare beneficiaries according to a new study by researchers at Johns Hopkins, including our Michael DiStefano

Quick Read

With much fanfare, federal officials required hospitals nationwide this year to post their “list” prices online. But it’s not yet clear how many are doing it, even as the government has taken the rare step of asking consumers to monitor hospital compliance.

Quick Read

A tragic snapshot of the opioid crisis. The pricing and availability of drugs — legal and illegal — illuminate how markets chase profits and reward innovation

Quick Read

A desperate but determined group of parents raised millions through golf tournaments and cocktail parties to support research for drugs to fight cystinosis, a rare, fatal childhood disease. They were ecstatic when a pill called Procysbi was approved in 2013

Quick Read

What one city did to fight high drug prices reveals a drug supply chain in which just about every link can benefit when prices go up

Quick Read